190 related articles for article (PubMed ID: 15350167)
1. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis.
Liu X; De Scheerder I; Desmet W
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):653-60. PubMed ID: 15350167
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
3. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.
Li JJ; Li J; Nan JL; Li Z; Zhen X; Mu CW; Dai J; Zhang CY
Med Hypotheses; 2007; 69(5):1004-9. PubMed ID: 17499449
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting stents: results, promises and problems.
van der Hoeven BL; Pires NM; Warda HM; Oemrawsingh PV; van Vlijmen BJ; Quax PH; Schalij MJ; van der Wall EE; Jukema JW
Int J Cardiol; 2005 Mar; 99(1):9-17. PubMed ID: 15721493
[TBL] [Abstract][Full Text] [Related]
5. Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
Jimenez-Valero S; Moreno R; Sanchez-Recalde A; Galeote G; Calvo L; Viana A; Lopez de Sá E; López-Sendón J
Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):137-46. PubMed ID: 19124417
[TBL] [Abstract][Full Text] [Related]
6. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory response after dexamethasone eluting coronary stent implantation.
Mut-Vitcu B; Drăgulescu SI; Drăgulescu A; El Kahlout A; Coroban A; Maximov D; Slovenski M
Rom J Intern Med; 2004; 42(1):119-27. PubMed ID: 15529601
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries.
Pires NM; Schepers A; van der Hoeven BL; de Vries MR; Boesten LS; Jukema JW; Quax PH
Cardiovasc Res; 2005 Dec; 68(3):415-24. PubMed ID: 16023630
[TBL] [Abstract][Full Text] [Related]
9. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study.
Han SH; Ahn TH; Kang WC; Oh KJ; Chung WJ; Shin MS; Koh KK; Choi IS; Shin EK
Am Heart J; 2006 Nov; 152(5):887.e1-7. PubMed ID: 17070150
[TBL] [Abstract][Full Text] [Related]
10. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
Vaina S; Ong AT; Serruys PW
Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
[TBL] [Abstract][Full Text] [Related]
11. Is inflammation a contributor for coronary stent restenosis?
Li JJ; Nie SP; Zhang CY; Gao Z; Zheng X; Guo YL
Med Hypotheses; 2007; 68(5):945-51. PubMed ID: 17045418
[TBL] [Abstract][Full Text] [Related]
12. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits.
Ohtani K; Egashira K; Nakano K; Zhao G; Funakoshi K; Ihara Y; Kimura S; Tominaga R; Morishita R; Sunagawa K
Circulation; 2006 Dec; 114(25):2773-9. PubMed ID: 17130346
[TBL] [Abstract][Full Text] [Related]
13. Use of a tacrolimus-eluting stent to inhibit neointimal hyperplasia in a porcine coronary model.
Huang Y; Salu K; Wang L; Liu X; Li S; Lorenz G; Wnendt S; Verbeken E; Bosmans J; Van de Werf F; De Scheerder I
J Invasive Cardiol; 2005 Mar; 17(3):142-8. PubMed ID: 15867441
[TBL] [Abstract][Full Text] [Related]
14. [Drug-eluting stents and other anti-restenosis devices].
Moreno R
Rev Esp Cardiol; 2005 Jul; 58(7):842-62. PubMed ID: 16022816
[TBL] [Abstract][Full Text] [Related]
15. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
Silber S
J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
[TBL] [Abstract][Full Text] [Related]
16. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury.
Scott NA
Adv Drug Deliv Rev; 2006 Jun; 58(3):358-76. PubMed ID: 16733073
[TBL] [Abstract][Full Text] [Related]
17. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of drug-eluting stents: current best available evidence.
Raja SG; Dreyfus GD
J Card Surg; 2006; 21(6):605-12; discussion 613-4. PubMed ID: 17073969
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
[TBL] [Abstract][Full Text] [Related]
20. Understanding the drug-eluting stent trials.
Coolong A; Kuntz RE
Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
